Modular Medical (NASDAQ:MODD – Get Free Report) and Nephros (NASDAQ:NEPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.
Earnings and Valuation
This table compares Modular Medical and Nephros”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Modular Medical | N/A | N/A | -$28.24 million | ($14.71) | -0.28 |
| Nephros | $18.79 million | 2.02 | $1.19 million | $0.07 | 50.00 |
Volatility & Risk
Modular Medical has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Nephros has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for Modular Medical and Nephros, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Modular Medical | 1 | 0 | 0 | 0 | 1.00 |
| Nephros | 0 | 1 | 1 | 0 | 2.50 |
Nephros has a consensus target price of $6.00, indicating a potential upside of 71.43%. Given Nephros’ stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Modular Medical.
Profitability
This table compares Modular Medical and Nephros’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Modular Medical | N/A | -286.34% | -216.26% |
| Nephros | 4.06% | 7.66% | 5.86% |
Insider and Institutional Ownership
27.5% of Modular Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 7.1% of Modular Medical shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Nephros beats Modular Medical on 12 of the 13 factors compared between the two stocks.
About Modular Medical
Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.
About Nephros
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Receive News & Ratings for Modular Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Modular Medical and related companies with MarketBeat.com's FREE daily email newsletter.
